Chief Executive Officer
Dr. Qunsheng Ji, the Chief Executive Officer of Sirius Therapeutics, is a seasoned pharmaceutical executive with near 30-year experience in drug discovery, translational medicine, and business leadership.
Prior to Sirius Therapeutics, Dr. Ji was Vice President and Head of Oncology and Immunology Unit at WuXi AppTec. Where he led team of over 1000 R&D personnel and research business enabling drug discovery and development for hundreds of pharmaceutical and biotech companies around the world. Prior to WuXi AppTec, Dr. Ji was Head of Bioscience, Asia and Emerging Market iMed of AstraZeneca. He also served as Director of Translational Medicine, overseeing AstraZeneca’s global translational medicine portfolio.
Dr. Ji started his industry career in the U.S where he served ONYX Pharmaceuticals and OSI Pharmaceuticals, respectively.
Dr. Ji obtained his Ph.D. degrees in Cell Biology from Peking Union Medical College and Vanderbilt University in the U.S. He also received Bachelor degree of Medicine in China
Dr. Ji is author of more than 50 peer-reviewed research articles and book chapters. In addition, he is a co-founder and vice chair of Sino Drug Discovery Association (SDDA).
Chief Scientific Officer
Dr. Curt Bradshaw, Chief Scientific Officer (CSO) of Sirius Therapeutics, is a highly-regarded pharmaceutical executive who has accumulated over 30 years of experience in drug and chemical development, including 11 years leading the development of siRNA therapeutics.
In the two decades prior to joining Sirius Therapeutics, Dr. Bradshaw had served in senior leadership positions in drug and chemistry development at multiple biotechs and large multinational pharmaceutical companies including CSO at NeuBase Therapeutics and Arrowhead Pharmaceuticals; CSO and Co-Founder at Tallac Therapeutics; CSO and Co-Founder at Solstice Biologics; and Vice President of Chemistry at the CovX Pharmaceutical unit of Pfizer.
Dr. Bradshow has a Ph.D. degree in Chemistry from Texas A&M University, the U.S.
SVP, Non-clinical Development
Dr. David Li, Senior Vice President of Non-clinical Development at Sirius Therapeutics, with 25 years of industry experience in drug development, including 14-year drug development in China.
Prior to joining Sirius Therapeutics, Dr. Li served in various leadership positions at biotechs and multinational pharmaceutical companies, including Chief Operations Officer at Youngene Therapeutics, Vice President of CMC and Supply Chain at LianBio, Associate Director of Pharmaceutical Development at AstraZeneca, Innovation Center China, and Senior Fellow at Novartis (China).
Dr. Li obtained his Ph.D. degree in Chemistry from the University of California, Irvine.
Chairman
David Wang, M.D., Ph.D., is a Partner and Senior Managing Director on OrbiMed Asia team, focused on Greater China.
Previously, he was a Managing Director at WI Harper Group, responsible for healthcare investments in China. He also previously served as Head of Business Development at Siemens Medical Solutions, where he directed corporate strategy and new businesses in molecular diagnostics and diagnostic imaging. Dr. Wang was a co-founder and EVP at First Genetic Trust, a personalized medicine company. During his tenure at Bristol-Myers Squibb, Dr. Wang was Chairman of The SNP Consortium Management Committee, the first group of its kind formed by pharmaceutical and technology industries to support the development of personalized medicine.
He received his M.D. from Peking University Medical School and his doctorate in Developmental Biology from the California Institute of Technology.
Board Director
Dr. Wei Li is the Founding Partner at Creacion Ventures.
Before founding Creacion Ventures, Dr. Li served as the management partner in 6 Dimensions Capital, the partner of Fidelity Biotechnology and Fidelity Growth Partners Asia, and the co-founder of Innovent.
Dr. Wei Li has successfully founded or involved in the founding of a series of biotechnology companies in China and overseas, including Innovent Biologics (stock code: 1801. HK), CStone Pharmaceuticals (stock code: 2616. HK), Ocumension Therapeutics (stock code: 1477. HK), and Dewpoint Therapeutics.
Dr. Wei Li holds a Ph.D. degree in Biochemistry from Harvard University and an MBA degree from the Northwestern University – Kellogg School of Management.
Board Director
Mr. Diyong Xu is the Principal at Orbimed U.S. and former investment banking analyst at Lazard Freres & Co.
Mr. Diyong Xu holds a Master of Science (M.S.) degree in Management Science and Engineering from Stanford University, a M.S. degree in Molecular and Cellular Biology from the Dartmouth Medical School, and a Bachelor of Science degree in Biology from the Zhejiang University in China.
Board Director
Mr. Kevin Yuan is the Chief Executive Officer at Shanghai Hankang Private Equity Management Co., Ltd.
Mr. Hong Yuanquan has more than 20 years of experience investing in China’s biopharmaceutical industry and has led the investment in over 40 early-stage biopharmaceutical companies, including some that already became industry leaders, such as InnoCare Pharma (9969. HK, 688428. SH), AkesoBio (9926. HK), Keymed Biosciences (2162. HK), Chipscreen Biosciences (688321. SH), Abbisko Therapeutics (2256. HK), and OPM Biosciences (688293. SH).
Mr. Kevin Yuan holds a Master degree in Management from Zhejiang University and an MBA degree from the China Europe International Business School (CEIBS).
Board Director
Dr. Qunsheng Ji is the Chief Executive Officer at Sirius Therapeutics.
Prior to Sirius, he was the Vice President and Head of the Oncology and Immunology Unit at Wuxi AppTec, and Head of BioScience and Director of Translational Medicine at Asia & Emerging Market iMed, AstraZeneca.
Dr. Qunsheng Ji holds a Doctor of Medicine (MD) degree from the First Military Medical University in China, and a Ph.D. degree in Cellular Biology from Vanderbilt University/Peking Union Medical College of the Chinese Academy of Medical Sciences.
Independent Director
Dr. Douglas Fambrough was the Founder, President and Chief Executive Officer of Dicerna Pharmaceuticals (a company that was acquired by Novo Nordisk for US$3.3 billion).
Dr. Douglas Fambrough holds a Ph.D. degree in Genetics from the University of California, Berkley, and a Bachelor degree in Biology from Cornell University.
Our lead investors have been investing in the global healthcare industry for over 20 years. Their portfolios cover a broad array of therapeutic areas and companies at various stages, from start-ups to large multinational enterprises.
Sirius Therapeutics, Inc., all rights reserved
为了更好的呈现效果，移动端请竖屏浏览
